Skip to main content

Carlsberg spin-out Traitomic raises 20 million euro Series A for non-GM trait discovery

Traitomic raised 20 million euro in a Series A led by Sofinnova Partners. The Carlsberg spin-out has delivered 116 traits to 47 customers.

Carlsberg spin-out Traitomic raises 20 million euro Series A for non-GM trait discovery

Traitomic, the Copenhagen company spun out of the Danish brewer Carlsberg, has raised 20 million euro in a Series A led by Sofinnova Partners. It is the first external investment in the business. The Export and Investment Fund of Denmark, Footprint Firm, Nordic Foodtech VC, PSV Hafnium and SVG Ventures also joined the round.

The company sells access to FIND-IT, a screening platform developed at the Carlsberg Research Laboratory to improve barley. It searches very large populations of conventionally bred plants and microbes for the specific genetic variants behind a wanted trait, then hands that variant to the customer to use in its own breeding programme or production strain. Because nothing is edited or engineered, the resulting products can be sold as conventional, which keeps them clear of the approval routes that apply to gene edited crops in the European Union.

Traitomic puts its record at 116 traits delivered to 47 customers across 32 organisms, with roughly 100 further traits in pre-commercial assessment at client sites. The team numbers about 30 people and works in three areas: plant breeding and seed, the food supply chain and precision nutrition, and biosolutions and industrial biotechnology. Applications run from flavour and nutrition to shelf life, drought tolerance and industrial enzymes.

The money goes on international expansion, starting with the United States and Australia, where Traitomic has kept a small presence for the past two years, and on widening the organism list towards algae and mushrooms. Chief executive and cofounder Gustav Hambraeus said: “We can develop traits very, very fast, and we are not bound by specific organisms.” Dealroom reports that Carlsberg has cut its holding to between 33 and 50 per cent, and places the round in the top 8 per cent of Series A deals recorded for Danish food companies.

For founders the interesting part is not the round size but the business model. Traitomic charges for a discovery service rather than for a seed or a licence, so each project ends with a variant the customer owns and breeds itself. That shortens the sales cycle with breeders who will not hand over germplasm, and it sidesteps the regulatory wait that has left gene edited traits commercially stranded in Europe while the new genomic techniques file grinds through Brussels. The number worth watching is not the 116 traits already delivered but how many of the 100 in pre-commercial assessment turn into products on a shelf, because that is where a discovery service either earns recurring revenue or stays a one off project fee.

Source: AgFunderNews

Carlsberg spin-out Traitomic raises 20 million euro Series A for non-GM trait discovery

Sofinnova Partners led the first external round for the Copenhagen company, whose FIND-IT platform locates useful genetic variants in conventionally bred populations without editing any DNA.

By Dirk Vandenhirtz

· Funding · Europe · 3 min

Traitomic, the Copenhagen company spun out of the Danish brewer Carlsberg, has raised 20 million euro in a Series A led by Sofinnova Partners. It is the first external investment in the business. The Export and Investment Fund of Denmark, Footprint Firm, Nordic Foodtech VC, PSV Hafnium and SVG Ventures also joined the round.

The company sells access to FIND-IT, a screening platform developed at the Carlsberg Research Laboratory to improve barley. It searches very large populations of conventionally bred plants and microbes for the specific genetic variants behind a wanted trait, then hands that variant to the customer to use in its own breeding programme or production strain. Because nothing is edited or engineered, the resulting products can be sold as conventional, which keeps them clear of the approval routes that apply to gene edited crops in the European Union.

Traitomic puts its record at 116 traits delivered to 47 customers across 32 organisms, with roughly 100 further traits in pre-commercial assessment at client sites. The team numbers about 30 people and works in three areas: plant breeding and seed, the food supply chain and precision nutrition, and biosolutions and industrial biotechnology. Applications run from flavour and nutrition to shelf life, drought tolerance and industrial enzymes.

The money goes on international expansion, starting with the United States and Australia, where Traitomic has kept a small presence for the past two years, and on widening the organism list towards algae and mushrooms. Chief executive and cofounder Gustav Hambraeus said: “We can develop traits very, very fast, and we are not bound by specific organisms.” Dealroom reports that Carlsberg has cut its holding to between 33 and 50 per cent, and places the round in the top 8 per cent of Series A deals recorded for Danish food companies.

For founders the interesting part is not the round size but the business model. Traitomic charges for a discovery service rather than for a seed or a licence, so each project ends with a variant the customer owns and breeds itself. That shortens the sales cycle with breeders who will not hand over germplasm, and it sidesteps the regulatory wait that has left gene edited traits commercially stranded in Europe while the new genomic techniques file grinds through Brussels. The number worth watching is not the 116 traits already delivered but how many of the 100 in pre-commercial assessment turn into products on a shelf, because that is where a discovery service either earns recurring revenue or stays a one off project fee.

Source: AgFunderNews

Back to AgTech News